Medpace Holdings, Inc.
MEDP
주식 순위
#1301
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a... Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
주가
$622.03
시가총액
$17.36B
변동 (1일)
0.38%
변동 (1년)
14.26%
국가
US
거래 Medpace Holdings, Inc. (MEDP)
카테고리
Healthcare
Medpace Holdings, Inc. (MEDP)의 수익
Jun 2026 기준 수익 TTM: $598.92M
Medpace Holdings, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $598.92M입니다. 2024년에 회사는 $475.92M의 수익을 올렸으며 이는 2023년의 수익 $335.68M과 증가입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Medpace Holdings, Inc.의 수익 기록 (2013 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $598.92M | 10.43% |
| 2025 | $542.38M | 13.96% |
| 2024 | $475.92M | 41.78% |
| 2023 | $335.68M | 18.67% |
| 2022 | $282.86M | 40.13% |
| 2021 | $201.85M | 19.77% |
| 2020 | $168.53M | 35.01% |
| 2019 | $124.83M | 32.87% |
| 2018 | $93.95M | 64.99% |
| 2017 | $56.95M | 159.35% |
| 2016 | $21.96M | -380.42% |
| 2015 | $-7.83M | -63.17% |
| 2014 | $-21.26M | -154.31% |
| 2013 | $39.15M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $7.61B | 1,170.45% |
US
|
|
| $4.76B | 695.09% |
US
|
|
| $-252.70M | -142.19% |
US
|
|
| - | - |
CN
|
|
| $1.66B | 176.83% |
US
|
